Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Gliosarcoma × encorafenib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1 CNS 1

Conditions

Melanoma 17 Colorectal Neoplasms 9 Brain Neoplasms 6 Colonic Neoplasms 5 Neoplasms 2 Neoplasm Metastasis 2 Thyroid Neoplasms 1 Skin Neoplasms 1 Recurrence 1 Rectal Neoplasms 1 Pancreatic Neoplasms 1 Multiple Myeloma 1 Gliosarcoma 1 Glioma 1 Glioblastoma 1 Disease Progression 1 Carcinoma, Non-Small-Cell Lung 1 Biliary Tract Neoplasms 1 Astrocytoma 1

Interventions

Temozolomide 80 Radiotherapy 47 Bevacizumab 29 Irinotecan 18 Radiation 15 Erlotinib Hydrochloride 14 Carmustine 13 Magnetic Resonance Spectroscopy 12 O(6)-benzylguanine 10 Chemotherapy, Adjuvant 10 sargramostim 8 Thalidomide 8 Imatinib Mesylate 8 Carboplatin 8 Gene Expression Profiling 6 Filgrastim 6 Drug Therapy 6 Surgical Procedures, Operative 5 Radiotherapy, Intensity-Modulated 5 Hydroxyurea 5 Gefitinib 5 pembrolizumab 4 aldesleukin 4 Topotecan 4 Immunohistochemistry 4 Etoposide 4 Dasatinib 4 Celecoxib 4 Biopsy 4 Aminolevulinic Acid 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03973918 2024-10-31

BRAF

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Terminated

5 enrolled 15 charts

Astrocytoma, Glioblastoma, Glioma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡